Biota Pharmaceuticals to Present at Ladenburg Thalmann 2015 Healthcare Conference
September 22 2015 - 4:15PM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a
biopharmaceutical company focused on the discovery and development
of direct-acting antivirals that address infections that have
limited therapeutic options, announced today that Biota's CEO &
President Joseph Patti, PhD will present a corporate overview at
the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday,
September 29, 2015 at 2:30 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed under "Events
and Presentations" in the Investors section of the Company's
website at www.biotapharma.com or at
http://wsw.com/webcast/ladenburg/bota.
A replay of the webcast will be archived for 30 days following
the presentation.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and
development of direct-acting antivirals to treat infections that
have limited therapeutic options and affect a significant number of
patients globally. The Company has four product candidates in
clinical development. These include vapendavir, an oral treatment
for human rhinovirus infections in moderate-to-severe asthmatics
that is currently being evaluated in the Company's ongoing Phase 2b
SPIRITUS trial; BTA074, a topical antiviral treatment in Phase 2
development topical antiviral treatment for genital warts caused by
human papillomavirus types 6 & 11; BTA585, an oral fusion (F)
protein inhibitor in Phase 1 development for the treatment of
respiratory syncytial virus (RSV) A & B infections; and
laninamivir octanoate, a one-time, inhaled treatment in Phase 2
development for influenza A and B infections. The Company also has
a preclinical stage RSV non-fusion inhibitor program that it
believes can complement its fusion-protein inhibitor BTA585. For
additional information about the Company, please visit
www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
CONTACT: Joseph M. Patti, PhD
President and Chief Executive Officer
(678) 221-3352
j.patti@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024